Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Emicizumab: Applications & Research

Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). Emicizumab is a bispecific factor IXa- and factor X-directed antibody.

Language: English [EN]
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
100%
More settings
100% 100% 100% 100% 100%

Emicizumab topic overview

The analysis highlights Applications and Research as prominent areas in the source structure around Emicizumab.

Related topics
21
Source areas
6
Connected nodes
27
Extracted relationships
49
Concept neighborhoods
14
Bridge connections
27

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Overview · 10 topics
Pharmacology · 4 topics
Adverse effects · 3 topics
Regulatory approvals · 2 topics
Medical uses · 1 topics
Research · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

AHFS/Drugs.com
Monograph
ATC code
B02BX06 (WHO)
CAS Number
1610943-06-0
ChemSpider
none
DrugBank
DB13923
Formula
C6434H9940N1724O2047S45

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Medical uses

Adverse effects

Pharmacology

Research

Regulatory approvals

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Emicizumab connects Entity context

The extracted context around Emicizumab shows recurring relationship patterns in the source. For example, Emicizumab → Breakthrough Therapy, FDA, HAVEN, Hemlibra, November, On October, This, VIII Another extracted example is Emicizumab → FIXa, FVIIIa, FX, IX, This, Unlike, VIII. Use these groups to spot repeated connection types before inspecting the individual relationships.

Emicizumab

Top relations

related to Regulatory approvals · 8
Emicizumab → Breakthrough Therapy, FDA, HAVEN, Hemlibra, November, On October, This, VIII
related to Mechanism of action · 7
Emicizumab → FIXa, FVIIIa, FX, IX, This, Unlike, VIII
Legal status · 5
Emicizumab → AU: S4 (Prescription only), CA: ℞-only / Schedule D, EU: Rx-only, In general: ℞ (Prescription only), US: ℞-only
is a · 2
Emicizumab → better therapy compared to the previous generations, bispecific factor IXa- and factor X-directed antibody.Emicizumab was first approved by the U.S
related to Additional HAVEN studies · 2
Emicizumab → HAVEN, The
related to Available forms · 2
Emicizumab → The, VIII
related to HAVEN clinical trial program · 2
Emicizumab → HAVEN, Phase III
related to Research · 2
Emicizumab → Phase, Studies
AHFS/Drugs.com · 1
Emicizumab → Monograph
ATC code · 1
Emicizumab → B02BX06 (WHO)

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

factor patients viii hemophilia inhibitors administration fda haven antibody prophylaxis approval therapy bispecific developed clinical trial compared drug subcutaneous studies

Emicizumab relationships Subject–Predicate–Object triples

TTTA extracted 49 structured relationships around Emicizumab. Examples in this analysis include Emicizumab → AHFS/Drugs.com → Monograph and Emicizumab → ATC code → B02BX06 (WHO). The table shows each extracted connection, where it came from and its confidence.

SubjectPredicateObjectConfidenceSrc
EmicizumabAHFS/Drugs.comMonograph1.00infobox
EmicizumabATC codeB02BX06 (WHO)1.00infobox
EmicizumabCAS Number1610943-06-01.00infobox
EmicizumabChemSpidernone1.00infobox
EmicizumabDrugBankDB139231.00infobox
EmicizumabFormulaC6434H9940N1724O2047S451.00infobox
EmicizumabKEGGD10821 Y1.00infobox
EmicizumabLegal statusAU: S4 (Prescription only)1.00infobox
EmicizumabLegal statusCA: ℞-only / Schedule D1.00infobox
EmicizumabLegal statusUS: ℞-only1.00infobox
EmicizumabLegal statusEU: Rx-only1.00infobox
EmicizumabLegal statusIn general: ℞ (Prescription only)1.00infobox
EmicizumabLicense dataUS DailyMed: Emicizumab1.00infobox
EmicizumabMedlinePlusa6220461.00infobox
EmicizumabMolar mass145639.02 g·mol−11.00infobox
EmicizumabOther namesACE910, RG6013, emicizumab-kxwh1.00infobox
EmicizumabPregnancy categoryAU: B21.00infobox
EmicizumabRoutes of administrationSubcutaneous1.00infobox
EmicizumabSourceHumanized1.00infobox
EmicizumabTargetActivated factor IX, factor X1.00infobox
EmicizumabTrade namesHemlibra1.00infobox
EmicizumabTypeWhole antibody1.00infobox
EmicizumabUNII7NL2E3F6K31.00infobox
Emicizumabis abispecific factor IXa- and factor X-directed antibody.Emicizumab was first approved by the U.S0.90text
Emicizumabis abetter therapy compared to the previous generations0.90text

Related concept clusters Concept neighborhoods

The concept neighborhoods around Emicizumab bring nearby vocabulary together. In this analysis, examples include Inhibitors, Prophylaxis and Factor. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

  • Emicizumab
    • Inhibitors
    • Prophylaxis
    • Factor
    • Subcutaneous
    • Antibody
    • Haven
    • Bleeding
    • Hemlibra
    • Regulatory
    • Study
    • Hemophilia
    • Bispecific
  • emicizumab
    • Inhibitors
    • Prophylaxis
    • Factor
    • Subcutaneous
    • Antibody
    • Haven
    • Bleeding
    • Hemlibra
    • Regulatory
    • Study
    • Hemophilia
    • Bispecific
  • bispecific monoclonal antibody
    • Antibody
    • Bispecific
    • Coagulation
    • Humanized
    • Activated
    • Hemlibra
    • Factor
    • Emicizumab
    • Bleeding
    • Developed
    • Mechanism
    • Regulatory
  • u.s. food and drug administration
    • Food
    • Compared
    • Fda
    • Therapy
    • Viii
    • Administration
    • Approximately
    • Drug
    • Replacement
    • Routine
    • Traditional
    • Factor
  • food and drug administration
    • Food
    • Compared
    • Fda
    • Therapy
    • Viii
    • Administration
    • Approximately
    • Drug
    • Replacement
    • Routine
    • Traditional
    • Factor
  • coagulation factor ix
    • Viii
    • Hemophilia
    • Inhibitors
    • Patients
    • Activated
    • Approximately
    • Coagulation
    • Factor
    • Mechanism
    • Replacement
    • Routine
    • Traditional
  • factor x
    • Viii
    • Hemophilia
    • Inhibitors
    • Patients
    • Activated
    • Approximately
    • Coagulation
    • Mechanism
    • Replacement
    • Routine
    • Traditional
    • Prophylaxis
  • factor viii
    • Factor
    • Viii
    • Hemophilia
    • Inhibitors
    • Patients
    • Administration
    • Approximately
    • Mechanism
    • Replacement
    • Routine
    • Traditional
    • Developed

Connections between topic areas Semantic bridges

For Emicizumab, one of the stronger structural bridges in this analysis connects Emicizumab with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3
Emicizumab — Overview · splits 17 ⟂ 11
Emicizumab — Pharmacology · splits 23 ⟂ 5
Emicizumab — Adverse effects · splits 24 ⟂ 4
Emicizumab — Regulatory approvals · splits 25 ⟂ 3

Map overview Semantic statistics

Emicizumab

Nodes28
Edges27
Triples49
Avg. degree1.93
Density0.071429
Components1

Source & methodology

TTTA analyzes the structure around Emicizumab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Applications & Research, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Emicizumab · EN edition · Analysis: TopicsToTalkAbout

For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.